Ferric derisomaltose achieves highest likelihood of ≥1000-mg dose administered and lowest outpatient transfusion rates among intravenous iron therapies in women with iron deficiency anemia and abnormal uterine bleeding: a real-world analysis
NCODA Oncology and Hematology Meeting Abstracts · 15.06.2026
DOI: 10.67209/aelg8729 ↗Kurz gefasst
Fachartikel in der Zeitschrift NCODA Oncology and Hematology Meeting Abstracts, online erschienen am 15.06.2026. Verfasst von Annette von Drygalski und 4 weiteren Autor:innen. Die Arbeit nennt 2 Literaturangaben.
Abstract (Originalsprache)
Abnormal uterine bleeding (AUB), a common gynecologic condition, can lead to iron deficiency anemia (IDA), which increases health complication risks and necessitates iron repletion. Intravenous (IV) iron products are a treatment modality for IDA; however, the amount of IV iron ordered varies among available products. These orders can differ from FDA-approved iron dosages; high-dose products—ferumoxytol (FXT), ferric carboxymaltose (FCM), and ferric derisomaltose (FDI)— have labeled dosing of at least 1000 mg, depending on the product. Furthermore, the impact of IV iron on reducing outpatient blood transfusions in women with AUB remains unknown.
Zitieren
APA
Drygalski, A. V., Patrick, Maksour, M., Polson, M., & Lewandowska, M. (2026). Ferric derisomaltose achieves highest likelihood of ≥1000-mg dose administered and lowest outpatient transfusion rates among intravenous iron therapies in women with iron deficiency anemia and abnormal uterine bleeding: a real-world analysis. NCODA Oncology and Hematology Meeting Abstracts. https://doi.org/10.67209/aelg8729
Vancouver
Drygalski AV, Patrick, Maksour M, Polson M, Lewandowska M. Ferric derisomaltose achieves highest likelihood of ≥1000-mg dose administered and lowest outpatient transfusion rates among intravenous iron therapies in women with iron deficiency anemia and abnormal uterine bleeding: a real-world analysis. NCODA Oncology and Hematology Meeting Abstracts. 2026. doi:10.67209/aelg8729
BibTeX
@article{Drygalski2026,
author = {Drygalski, Annette von and Patrick and Maksour, Manale and Polson, Michael and Lewandowska, Magdalena},
title = {Ferric derisomaltose achieves highest likelihood of ≥1000-mg dose administered and lowest outpatient transfusion rates among intravenous iron therapies in women with iron deficiency anemia and abnormal uterine bleeding: a real-world analysis},
journal = {NCODA Oncology and Hematology Meeting Abstracts},
year = {2026},
doi = {10.67209/aelg8729}
}
EUVIMED